The number of prevalent cases of AD in the countries under study will increase by 43% over the 10-year forecast period, from 384,000 to 548,000. Of the countries considered in this analysis,…
Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in the Asia-Pacific region. We report both the incidence and…
Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in Europe (Austria, Belgium, Czech Republic, Denmark, Finland,…
Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in the Americas (Argentina, Canada, Chile, Colombia, and Peru). We…
Clarivate Epidemiology’s coverage of Alzheimer’s disease (AD) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India, Mexico…
Clarivate Epidemiology’s coverage of AD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key AD patient populations covering 171 countries and more than 99% of…
Alongside putative disease-modifying therapies, the late-phase pipeline in Alzheimer’s disease (AD) features several therapies for the treatment of behavioral symptoms in AD. Symptoms such as…